A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
CA 2266325 C · Owner: Genentech, Inc. · Inventors: Umansky, Samuil; Melkonyan, Hovsep
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An isolated polynucleotide at leat 60 % homologous to SEQ ID NO: 1 3, 5 or 18 , encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of .alpha.SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples including cancers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 24, 1997 and granted July 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 24, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 24, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.